JD HEALTH

6618
41.2801.52% ( +0.620 )
Delay Closed: Nov 16, 16:08:11

Overview

JD HEALTH (6618)

JD Health International Inc., an investment holding company, engages in the operation of an online healthcare platform in the People’s Republic of China. It pro...

Open
41.000
High
42.240
Low
40.660
Prev. Close
40.660
Volume
7.11M
Turnover
295.06M
Avg Price
41.487
Bid/Ask Ratio
-85.97%
Amplitude
3.89%
52wk High
71.700
Volume Ratio
0.87
Turnover Ratio
0.22%
52wk Low
31.840
HK Mkt Cap
131.70B
Market CapHKD
131.70B
P/ETTM
18.40
P/EDynamic
16.64
P/EStatic
--
EPSTTM
2.24
EPSDynamic
2.48
EPSStatic
--
BVPS
22.18
P/B
1.86
HK Shares
3.19B
Dividend YieldTTM
--
DividendTTM
--
Shares
3.19B
Min lot size
50
Currency
HKD

JD HEALTH Analyst Rating

View more

Forecast & Rating

Nov 3, 2026
Price forecast
HK$68.9867.09%
Forecast & RatingStrong buy
17analysts
  • Strong buy76.47%
  • Buy17.65%
  • Hold5.88%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 16

    JD Health rose 1.52% to close at HK$41.28, rebounding from last week's 5.44% decline with morning strength followed by afternoon moderation, supported by robust recent earnings and strategic initiatives. Q2 net profit surged 39.53% year-over-year with operating profit jumping 57.53%, demonstrating significant improvement in profitability and operational leverage; the company also announced a strategic partnership with Pfizer China, expanding its internet healthcare ecosystem. From a valuation standpoint, despite today's recovery, the stock remains 26.74% below year-to-date opening price and trades 42.43% below its 52-week peak of HK$71.70, still at historical lows. Technically, it trades above the 60-day moving average of HK$37.35. Most brokers maintain buy ratings, reflecting confidence in the company's medium-term fundamental recovery despite recent weakness.

  2. Nov, 13

    JD Health retreated about 1.1% today to close at HK$40.66, following a robust 9.63% rally last week which likely triggered profit-taking. The company's recent financials remain compelling: Q2 revenue reached HK$23.61 billion, growing 22.13% year-over-year, while net profit of HK$1.98 billion surged 39.53% YoY with EPS of HK$0.6179 up 39.24%, underscoring steady business momentum. Strategically, a recent partnership with Pfizer China strengthens its international healthcare positioning, while most brokers maintain buy ratings. From a valuation perspective, the stock trades at a 43.29% discount to its 52-week high of HK$71.7 set in January, sits above the 60-day moving average of HK$37.30, and carries a reasonable PE multiple of 18.13 with market cap around HK$129.7 billion. However, the substantial decline from January's peak suggests any sustained recovery requires fresh catalysts.

  3. Nov, 12

    JD Health declined approximately 2% to HKD41.12 today, primarily due to profit-taking following recent gains. The stock benefited from a strategic partnership with Pfizer China in recent weeks, with most brokers maintaining buy ratings that contributed to a 9.63% weekly gain, though year-to-date losses remain substantial at -27% from the HKD56.35 opening price. Fundamentals remain solid with Q2 EPS of HKD0.6179, up 39.24% year-over-year, and operating revenue of HKD23.614 billion, advancing 22.13%. Current market cap reaches HKD131.193 billion with a PE ratio of 18.33x and PB ratio of 1.85x, down 42.65% from the 52-week high of HKD71.7 but trading above the 60-day moving average of HKD37.27. Intraday trading reflected mixed sentiment, with morning weakness to HKD41.00 followed by afternoon recovery to the close, indicating market divergence on healthcare platform valuations.

  4. Nov, 11

    6618.HK closed down HKD0.88 or 2.06% at HKD41.96 versus yesterday's HKD42.84, exhibiting pronounced intraday session divergence. Morning trading remained relatively stable within the HKD42.14-42.78 range, reaching an intraday high of HKD42.78, but afternoon trading deteriorated, with the stock sliding from HKD42.44 open to HKD41.96 close, representing a 1.13% afternoon decline. Daily turnover reached 8.18M shares worth HKD345M. Against the backdrop of a stronger Hong Kong market with the Hang Seng Index up 739 points, the stock demonstrated relatively weak performance, with an intraday low of HKD41.82 and trading range of approximately 2.3%. Historical price positioning and financial metrics remain unavailable for this period, preventing valuation assessment.

  5. Nov, 10

    JD Health edged down to HKD 42.84 today, a decline of 0.37%, primarily reflecting profit-taking following last week's rally of 9.63%. Fundamentals remain robust: Q2 revenue hit HKD 23.61 billion, up 22.13% year-over-year, with net profit of HKD 1.985 billion, up 39.53% YoY, and EPS of HKD 0.6179, up 39.24%. Q1 showed comparable momentum with net profit growth of 40.38%. Strategically, the company recently established a partnership with Pfizer China, expanding its internet healthcare ecosystem. Valuation is reasonable at PE 19.1 and PB 1.93, with most brokers maintaining buy ratings. Regarding price positioning, the stock has declined 23.98% year-to-date from HKD 56.35 and remains 40.25% below its 52-week high of HKD 71.7, though it trades above both the 20-day moving average of HKD 39.06 and 60-day moving average of HKD 37.18, suggesting the market retains confidence in medium-term growth prospects.

News

Bullish vs. Bearish — Last 3 Months

19.6k followers · 0 opinions
▲Bullish50%
50%Bearish▼
  • F
    Fattycat
    Featured

    $JD.com(JD.US)$JD-SW(09618.HK)

    🚀 JD.com Unleashes “Physical AI” - The 5-Year Plan That Will Change Everything!

    JD.com shares closed at HK$105.500 with a slight dip recently. But look past that short-term move and you will see a massive five-year vision taking shape.

    JD is moving beyond software and right into the real world with an ambitious Physical AI acceleration plan.

    🤖 Massive Automation

    JD Logistics plans to deploy 3 million robots plus 1 million unmanned vehicles and 100,000 drones.

    🏢 New Infrastructure

    The company will build 80 RoboBase industrial bases across the country.

    📱 AI-Powered Shopping

    The new App Version 16.0 introduces Dongdong. This AI assistant helps with everything from product selection to arranging housekeeping services.

    🩺 Smart Healthcare

    JD Health has unveiled a fully intelligent medical AI agent that connects users with consultations and home testing services.

    From warehouse floors to your smartphone, JD.com is going all in on a hardware-heavy AI future.

    Check out the latest infographic for the full picture of this strategic shift!

    Not financial advice. Do your own DD☺️.

    图片 1,共 2 张
    < 09618JD-SW Closed 09.1016:08:44 123.6k Quotes Overview Financials 105.500 -0.8
  • P
    Profit

    Zai Lab's commercialization and licensing model in China has seen multiple products included in the national reimbursement drug list (NRDL), with high visibility for revenue growth in 2026.

    JD Health, a leader in internet healthcare, continues to see growth in monthly active users and online penetration of prescription drugs. Improved consumer sentiment post-ceasefire is beneficial for platform transaction volume.

    Insilico Medicine is a globally representative company in AI-driven drug discovery, with pipeline progress being a short-term catalyst. Its latest funding round valued the company at over $600 million, and it is currently in a window of valuation re-rating as it transitions from an AI tool provider to a clinical-stage pipeline company.

  • M
    momoM

    $XTALPI(02228.HK) Goldman Sachs launched the "China AI Healthcare Index" today, with Pharmaron as the top-weighted stock $ALI HEALTH(00241.HK)$JD HEALTH(06618.HK)$PA GOODDOCTOR(01833.HK)$YIDU TECH(02158.HK)$MircroPort Medbot-B(02252.HK)

    图片 1,共 1 张